Home/Filings/4/0000914190-13-000432
4//SEC Filing

Talon Therapeutics, Inc. 4

Accession 0000914190-13-000432

CIK 0001140028operating

Filed

Jul 17, 8:00 PM ET

Accepted

Jul 18, 4:14 PM ET

Size

24.4 KB

Accession

0000914190-13-000432

Insider Transaction Report

Form 4
Period: 2013-07-17
DEITCHER STEVEN R
DirectorPresident & CEO
Transactions
  • Disposition to Issuer

    Stock Option (right to buy)

    2013-07-171,000,0000 total
    Exercise: $0.64Exp: 2023-01-25Common Stock (1,000,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2013-07-171,000,0000 total
    Exercise: $0.91Exp: 2022-02-17Common Stock (1,000,000 underlying)
  • Disposition to Issuer

    Common Stock

    2013-07-17184,1920 total
  • Disposition to Issuer

    Stock Option (right to buy)

    2013-07-17312,5000 total
    Exercise: $0.76Exp: 2020-02-16Common Stock (312,500 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2013-07-1787,5000 total
    Exercise: $0.92Exp: 2020-06-07Common Stock (87,500 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2013-07-17100,0000 total
    Exercise: $6.60Exp: 2017-05-21Common Stock (100,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2013-07-1725,0000 total
    Exercise: $6.96Exp: 2017-08-24Common Stock (25,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2013-07-17162,5000 total
    Exercise: $4.48Exp: 2017-12-14Common Stock (162,500 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2013-07-1775,0000 total
    Exercise: $0.56Exp: 2019-02-24Common Stock (75,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2013-07-171,635,0000 total
    Exercise: $0.49Exp: 2020-12-21Common Stock (1,635,000 underlying)
Footnotes (2)
  • [F1]The reporting person received $0.056 per share plus one contingent value right (CVR) per share in accordance with the terms of a Stock Purchase Agreement by and among Talon Therapeutics, Inc., Spectrum Pharmaceuticals, Inc. and Eagle Acquisition Merger Sub, Inc. dated July 16, 2013 (the "Purchase Agreement"). Each CVR represents the right to receive a maximum future cash payment of approximately $0.968 per CVR from Spectrum based upon the achievement of certain sales and regulatory milestones.
  • [F2]This stock option was cancelled pursuant to the terms of the Purchase Agreement.

Issuer

Talon Therapeutics, Inc.

CIK 0001140028

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001140028

Filing Metadata

Form type
4
Filed
Jul 17, 8:00 PM ET
Accepted
Jul 18, 4:14 PM ET
Size
24.4 KB